191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC.

Peters, S.; Antonia, S.; Goldberg, S.B.; Heymach, J.V.; Kim, E.S.; Nakagawa, K.; Papadimitrakopoulou, V.; Mukhopadhyay, P.; McIntosh, S.; Rizvi, N.A.

doi:10.1016/S1556-0864(16)30300-8

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC.

Détails

Demande d'une copie

ID Serval

serval:BIB_D72A5BC15636

Type

Autre: (aucun autre type ne convient)

Collection

Publications

Institution

UNIL/CHUV

Titre

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC.

Auteur⸱e⸱s

Peters S., Antonia S., Goldberg S.B., Heymach J.V., Kim E.S., Nakagawa K., Papadimitrakopoulou V., Mukhopadhyay P., McIntosh S., Rizvi N.A.

ISBN

1556-1380 (Electronic)

ISSN-L

1556-0864

Date de publication

2016

Langue

anglais

OAI-PMH

oai:serval.unil.ch:BIB_D72A5BC15636

DOI

10.1016/S1556-0864(16)30300-8

Pubmed

27198327

Open Access

Oui

Création de la notice

06/06/2016 17:26

Dernière modification de la notice

20/08/2019 16:56

Données d'usage

SERVAL

serveur académique lausannois

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC.

Détails